期刊
CLINICAL NEUROPHARMACOLOGY
卷 27, 期 6, 页码 278-280出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.wnf.0000150866.98887.77
关键词
zonisamide; migraine; prevention; anticonvulsants; prophylaxis
Objectives: Zonisamide is a novel anticonvulsant drug with multiple mechanisms of action, many of which may confer efficacy in the treatment of migraine headaches. This study investigated the use of open-label zonisamide in treating patients with refractory migraine headaches. Methods: Thirty-four migraine patients were initiated on a 100-mg/day zonisamide dosage, which was titrated to 400 mg/day as tolerated. Mean headache severity, frequency, and duration were assessed before and 1, 2, and 3 months after initiation of zonisamide therapy. Results: Statistically significant improvements in headache severity (P < 0.01), duration (P < 0.05), and frequency (P < 0.05) were evident after 1 month of zonisamide therapy and were carried through month 3 of treatment. Zonisamide was well tolerated, with only 4 patients (11.8%) discontinuing for adverse events, including dysphoria (n = 2) and difficulty concentrating (n = 2). Other adverse events were transient and tolerable. Conclusions: These results suggest that zonisamide may be a safe and effective adjunctive agent for migraine prevention. Double-blind studies are warranted to confirm these findings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据